NCT00671242

Brief Summary

Purpose: L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer (NSCLC). Method: Thirty-seven NSCLC patients were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. Uptake of PET tracers was evaluated with standardized uptake value. VEGF, CD31, CD34, LAT1 and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical staining, and correlated with the clinicopathologic variables and the uptake of PET tracers.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 30, 2008

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 5, 2008

Completed
Last Updated

May 5, 2008

Status Verified

January 1, 2008

First QC Date

April 30, 2008

Last Update Submit

May 2, 2008

Conditions

Keywords

Fluorine-18-α-methyltyrosine,Positron emission tomography,Fluorine-18-fluorodeoxyglucose,Lung cancer,AngiogenesisThe median VEGF rate was 45% (range, 10-78%).High expression was seen in 30 patients (81%, 30/37).VEGF expression was statistically associated with progressively growing microvessel count.

Study Arms (2)

I

L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer

Nuclear

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who underwent a thoracotomy within 4 weeks after 18F-FMT PET and 18F-FDG PET study
  • Histology is non-small cell lung cancer

You may not qualify if:

  • Patient who received neoadjuvant chemotherapy or radiotherapy before surgery
  • Patients who have insulin-dependent diabetes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gunma University Graduate School of Medicine

Showa-machi, Maebashi, Gunma, 371-8511, Japan

Location

Related Publications (1)

  • Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci. 2009 Apr;100(4):753-8. doi: 10.1111/j.1349-7006.2008.01077.x. Epub 2009 Jan 12.

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell LungLung Neoplasms

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 30, 2008

First Posted

May 5, 2008

Last Updated

May 5, 2008

Record last verified: 2008-01

Locations